Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-25-069816
Filing Date
2025-05-13
Accepted
2025-05-13 07:57:24
Documents
80
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q mreo-20250331.htm   iXBRL 10-Q 1683805
2 EX-31.1 mreo-ex31_1.htm EX-31.1 26297
3 EX-31.2 mreo-ex31_2.htm EX-31.2 25796
4 EX-32.1 mreo-ex32_1.htm EX-32.1 8905
5 EX-32.2 mreo-ex32_2.htm EX-32.2 8640
  Complete submission text file 0000950170-25-069816.txt   8571962

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT mreo-20250331.xsd EX-101.SCH 1595217
83 EXTRACTED XBRL INSTANCE DOCUMENT mreo-20250331_htm.xml XML 1435012
Mailing Address ONE CAVENDISH PLACE FOURTH FLOOR LONDON X0 W1G0QF
Business Address ONE CAVENDISH PLACE FOURTH FLOOR LONDON X0 W1G0QF 4403330237300
Mereo BioPharma Group plc (Filer) CIK: 0001719714 (see all company filings)

EIN.: 000000000 | State of Incorp.: X0 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38452 | Film No.: 25937208
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)